Opinion|Videos|December 10, 2025

New Trial Data Suggests Aztreonam-Avibactam Maintains Strong Performance Against Highly Resistant Infections

Joshua Rosenberg, MD, continues the discussion on the REVISIT study, which showed comparable—or lower—28-day mortality rates than meropenem/colistin despite treating a higher proportion of patients with metallo-β-lactamase–producing pathogens.

A recent analysis of 28-day mortality data from a comparative trial highlights the promising performance of aztreonam-avibactam, particularly in patients battling highly resistant infections. The study evaluated outcomes across two major infection types: complicated intra-abdominal infections (cIAI) and hospital-acquired or ventilator-associated pneumonia (HAP/VAP), with enrollment skewed nearly 2:1 toward the aztreonam-avibactam.

In the cIAI cohort, mortality rates were low and comparable between the two treatment groups. Four patients (1.9%) in the aztreonam-avibactam group died, versus three patients (2.9%) receiving meropenem with optional colistin—differences largely explained by the higher number of patients enrolled in the investigational arm. These findings suggest noninferiority in a population with generally similar clinical severity.

More striking results emerged in the HAP/VAP subgroup. Here, eight of 74 patients (12%) treated with aztreonam-avibactam died, compared with seven of 36 patients (19.4%) in the meropenem/colistin group. Although small sample sizes limit definitive statistical conclusions, the percentage difference favors aztreonam-avibactam—especially considering the greater burden of metallo-β-lactamase (MBL) producers. Six patients in the aztreonam-avibactam arm had MBL infections, compared with only one in the comparator group.

Because MBL-producing organisms represent a rapidly growing global threat—and remain resistant to most existing antibiotics—the ability of aztreonam-avibactam to achieve comparable or better survival in sicker, more resistant cases is noteworthy. With data suggesting resilience against both traditional and emerging resistance mechanisms, this combination therapy may play a critical future role as MBL prevalence continues to rise.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.